ERBB2 and neoplasm: To evaluate the influence of trastuzumab on DFS in HER-2-positive patients, we examined several factors traditionally used in prognosis prediction, such as age, tumor size and grade, lymph node involvement, HR status, and the SII score as a predictor of inflammation.